Clinical trials: High-grade Glioma
Malignant Glioma
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy.
- Trial name
- NCT01991977
- Testing
- Diffusion Weighted Imaging, Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mayo Clinic
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Glioma
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified.
- Trial name
- NCT02540161
- Testing
- Sym004 - 18 mg/kg, Sym004 - 24 mg/kg
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Annick Desjardins
Glioblastoma, Recurrent Glioblastoma
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent).
- Trial name
- NCT04590664
- Testing
- Verteporfin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma
- Trial name
- NCT03210714
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma
Low Dose Naltrexone for Glioma Patients
To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
- Trial name
- NCT01303835
- Testing
- LDN
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Katy Peters
Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain
Trial of C134 in Patients With Recurrent GBM
The purpose of this project is to obtain safety information in small groups of individuals, scheduled to receive escalating doses of C134, a cancer killing virus (HSV-1) that has been genetically engineered to safely replicate…
- Conditions
- Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain
- Trial name
- C134-HSV-1 (NCT03657576)
- Testing
- C134
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Alabama at Birmingham
Oligodendroglioma, Astrocytoma
First in Patient Study for PF-06840003 in Malignant Gliomas
This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.
- Conditions
- Oligodendroglioma, Astrocytoma, Malignant Glioma
- Trial name
- NCT02764151
- Testing
- PF-06840003
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Pfizer
Glioma
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
The prodrug, 5-Aminolevulinic acid (ALA), has been shown to lead to intracellular accumulation of fluorescent porphyrins in high grade malignant gliomas in the brain.
- Trial name
- ALA (NCT01116661)
- Testing
- 5-Aminolevuline Acid (ALA)
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- University of California, San Francisco
Glioblastoma Multiforme, Glioma
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
Objectives: 1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or progressive malignant gliomas.
- Trial name
- NCT00412542
- Testing
- Thalidomide, CPT-11, MRI Scan
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Gliomas, CNS
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
The purpose of this study is to test the effectiveness of perifosine in preventing further tumor growth using the established optimal dose of the drug.
- Conditions
- Malignant Gliomas, CNS, Brain Cancer, Cancer
- Trial name
- NCT00590954
- Testing
- Perifosine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Glioma
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab.
- Trial name
- NCT00859222
- Testing
- LBH589, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Patrick Y. Wen, MD
Malignant Glioma
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
The purpose of this study is to see if the addition of the investigation drug called pembrolizumab (Keytruda®) to radiation therapy and bevacizumab (Avastin®) is safe and can help with controlling the growth of tumors, in…
- Trial name
- NCT02313272
- Testing
- Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Malignant Glioma
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
The purpose of this study is to determine if Nuvigil® improves fatigue experienced by people receiving external beam radiation therapy for the treatment of malignant gliomas.
- Trial name
- NCT01400958
- Testing
- Nuvigil®
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Cancer
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
1. Primary Objective: To determine the efficacy and tolerability of palonosetron and dexamethasone in preventing acute CINV in brain tumor patients during the first 24 hours of receiving Irinotecan /Bevacizumab regimens. 2.
- Trial name
- NCT00636805
- Testing
- Palonosetron (Aloxi) and Dexamethasone
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Astrocytoma, Glioma
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine.
- Conditions
- Astrocytoma, Glioma, Oligodendroglioma
- Trial name
- NCT00360828
- Testing
- Irinotecan Hydrochloride (HCI) Treatment, Continued Irinotecan Hydrochloride (HCI) Treatment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Glioblastoma Multiforme, Anaplastic Oligoastrocytoma
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT02026271
- Testing
- Ad-RTS-hIL-12, veledimex
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma Multiforme, Glioblastoma
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
- Trial name
- NCT02663271
- Testing
- Bevacizumab, Optune, Brain MRI
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida